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INT1IODIJCTTON
Among the substances of low molecular weight, phenyihydrazine is one of the
strongest skin-sensitizing agents known, and epidermal allergies in individuals
engaged in the preparation or the use of this compound in chemical laboratories
or industrial plants, are common occupational diseases. Because of the frequency
of this occurrence, W. Jadassohu (I) chose this substance for experimental sen-
sitization of guinea-pigs and found that just as easily as sensitizations occur in
men under natural conditions of exposure, so are experimental sensitizations of
guinea-pigs readily established.
An explanation of the particularly potent allergenic property of phenyl-
hydrazine has not been established, but it is most probable that the strong
affinity of this substance for proteins and certain other constituents of the animal
body plays an important role.
Within recent years a number of new hydrazine derivatives with interesting
pharmacological properties have been synthesized and evaluated by Druey
and Rengier (2), Grosset al (3), Bein et al (4), and Craver et al (5). Among them,
1-hydrazinophthalazine (Ba 5968, Naphazoline, Apresoline) and 1 ,4-dihydra-
zinophthalazine (Ba 7441, Nepresol) have been introduced in the clinic as hypo-
tensive agents (Page and Corcoran (6), Schroeder (7), Bein et al(s), and Esselier
et al (9)). In view of the strong allergenic properties of phenyl-hydrazine,it was
of interest to determine whether 1-hydrazinophthalazine (hereafter referred to
as 1-HP) possesses allergenic properties similar to that of phenylhydraziue.
EXPERIMENTAL
A. Sensitization Procedure. Female guinea-pigs, weighing between 250 and 350 grams were
injected intradermally on the shaven left flank with 0.1 ml. amounts of an 0.5% aqueous
solution of 1-HP at each of three sites on three alternate days. In this concentration, the
compound was found to have no primary irritating properties, since the injection yielded
virtually no evidence of local inflammation. On the 21st day, following the first sensitizing
dose, the animals were challenged intradermally on the opposite shaven flank with 0.1 ml.
amounts of an 0.5% solution of 1-HP, and the ensuing reactions evaluated 24 to 48 honrs
later.
B. Substances studied.
1. .Tlydrazinophthetezines.
AN /\( 'y N
•HC1 1-hydrazinophthalazine HC1, Ba 5968
(Naphazoline, Apresoline or 1-HP)
NH—NH2
* From the Research Department of CIBA Pharmaceutical Products, Inc., Summit,
New Jersey.
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NH—NH2
112804 i,4-dihydrazinophthalazine H2S04, Ba
N 7441 (Nepresol)
NH—NH2
CH4
•HC1 1-hydrazino-4-methyl-phthalazine HC1, Ba
6130
NH—NIL
Cl
,'\ /\N
•HCI 1-hydrazino-4-chloro-phthalazme HC1, Ba
N
NH— N 112
•HC1 1-hydrazino-4-hydroxy-phthalazineHCl, Ba
13049
NH—Nil2
4 formaldehyde 1-phthalazinyl-hydrazone, Ba
7126
NH—N=CH2
CH3 pyruvie acid 1-phthalazinyl-hydrazone, Su
NH—N=C
CO OH
[j\ I •CH3I i-hydrazino-phthalazine methiodide, BaN 12791
NH—NH2
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2. Hydrazino derivatives containing other ring systems.
NH— NH2
•HC1 4-hydrazino-cinnoline 1101, Ba 6905
N'
1
•21101 2,3-dihydrazino-quinoxaline 21101. Ba 12890
9\N7_M1112
•HC1 1-hydrazino-isoquinoline HO!, Ba 7406
NH—NH2
•H01 2-hydrazino-quinoline 1101, Ba 12664
¼%9\NC_MT2
O H6 5 N •11O1 3-hydrazino-6-phenyl-pyridazine HC1, Ba
H N—NH—'2 N •HNO2 3,6-dihydrazino-pyridazine nitrate, Ba
LjJ__NH__NH,
13504
k 2-hydrazino-6-propyl-4-pyrimidol, Su 1998t
[3
NH—NH2
0/
0—NH—NH2
isonicotinic acid hydrazine (Isoniazid)
N /
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3. Phthalazines, Without Hydrazino Groups.
HC1 phthalazine HC1, Ba 7182
CH2 CO OH
4hydroxy-i-phtha1azinc acetic acid, Su 2106
N
OFT
s-triazolo [3, 4-ajphtha]azinc, Ba 7127
N—N
•HC1 1-arnino-phthalazinc HC1, Ba 12668
NH2
J\NH 1- (2H)phthalazonc, Su 2283
0
4. Miscellaneous.
NH2
p -ph an ylcncdiaminc
NH2
RESULTS
I. Sensitization with 1-hydrazinophthalazine (1-HP)
a. Flare-up reactions. During the fifth and seventh day following the first
injection, the injection sites showed no signs of inflammation; hetween the 7th
and 12th day however, they "flared up" in a number of the animals.
These flare-up reactions resembled those described by Frei (10) and Sulz-
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berger (11) in sensitization experiments with neoarsphenamine, and subse-
quently observed by others during sensitizations to a variety of other compounds.
They persisted for 3 to 5 days and varied from slight infiltrations to strong
inflammation with central necrosis.
b. Challenge reactions. No immediate whealing reaction was observed. Hyper-
sensitivity was indicated by a delayed, tuberculin-type challenge reaction which
developed several hours after the injection.
The results of a typical experiment indicating the degree of flare-up and the
allergic response to three successive challenge injections are summarized in
Table 1.
In the experiment recorded in Table 1, flare-up reactions were observed in
seven of the ten sensitized animals. Upon the first challenge ore the 21st day,
eight animals presented an appreciable degree of cutaneous sensitivity of the
delayed type which increased considerably upon subsequent challenge. After
the third challenge injections, all animals had become strongly sensitized.
Intensification of the hypersensitive state upon repeated application of an
antigen is frequently observed in allergic diseases. On the other hand, repeated
challenges may also lead to a diminution of the reactivity or even to complete
desensitization. In order to establish whether continued challenges of guinea-pigs
TABLE 1
The results of the lgt, 2nd and 3rd cutaneous challenge injections in guinea-
pigs sensitized to 1 -hydrazinophthalazine
Guinea-Pig
Number
Flareup Reactions(7th to 12th day)
Delayed type Reactions Observed at Challenge Site
__________
1st challenge
(21st day)
2nd challenge
(29th day)
3rd challenge
(47th day)
—
1
2
3
4
5
6
7
8
9
10
+
+
+
0
+
0
0
+
+
+
++
++
+
0
++
+
0
++
+
++
+
++
0
0
++
++
++
++
++
++
+++
+++
++
--+
+++
+++
++
+++
+++
++
Controls
1 0
2 0
3 0
4 0
5 0
6 0
Note: 0, +, ++, +++ denote increasing degrees of reactivity. The days indicated in
the column headings refer to the time elapsed from the day of the first sensitizing injec-
tion.
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TABLE 2
Intensification of dermal hypersensitivity to 1-hydrazinophthalazine upon
repeated challenge. First challenge dose administered 21 days after
initial sensitizing injection
Challenge Number ofAnimals
Number of Animals Exhibiting Various Degrees of Delayed Type
of Hypersensitivity
++++ +++ ++ + 0
1st
2nd
3rd
4th
5th
6th
30
30
35
29
29
15
0
0
0
4
5
12
0 3
0 11
20 I 14
16 I 8
20 4
3 0
7
7
1
1
I 0
0
20
12
0
0
0
0
further intensify the state of hypersensitiveness to 1-HP or result in a decrease
of the established sensitivity, a series of animals was challenged repeatedly over
a period of three months.
Thirty normal guinea-pigs were sensitized to 1-HP as described above and
challenged six times at intervals of approximately 10 to 14 days. During the
third challenge, five additional sensitized animals from the preceding experiment
were included (Table 2).
It is apparent from these results (Table 2) that an increasing degree of dermal
hypersensitivity develops as a consequence of repeated challenge injections.
Upon the sixth challenge, given three months after the administration of the
first sensitizing injection, all animals without exception exhibited + + + or
+ + + + reactions. In no instance were signs of desensitization observed.
II. Gros.s-sensitization experiments with compounds chemically related to 1-HP
Having established that 1-HP was capable of sensitizing guinea-pigs, it was
of interest to determine whether the hypersensitivity thus developed was re-
stricted to the sensitizing agent or whether, as is the case with many allergens,
it extended to chemically related substances. Accordingly, a number of such
compounds were tested for cross-reactivity in guinea-pigs made strongly allergic
to 1-HP. In order to minimize individual differences among the animals, the
distribution of various compounds was randomized so that each guinea-pig
received a different combination of test injections. The results of several cross-
sensitization experiments are incorporated in Table 3. According to these data,
the following observations may be made:
1. Primary sensitization to 1-HP was simultaneously and to an almost equal
degree directed against a number of closely related hydrazinophthalazines bear-
ing substitutions on the nitrogen-containing ring, such as a methyl- (Ba 6130),
chloro-(Ba 7349), hydroxy-(Ba 13049) or a second hydrazino-group (Ba 7441).
2. Compounds bearing substitutions on the hydrazino group, as for instance
Su 2031 and Ba 7126, elicited weaker manifestations of cross-sensitivity than
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TABLE 3
Cross-sensitization reactions obtained with various hydrazines, phthalazines and
related compounds in guinea-pigs sensitized to 1-hydrazinophthalazine
Compound
Number
of
Animals
Used
Number of Guinea-Pigs with Various
Degrees of Delayed Type of
Cutaneous Reaction
——.
+++ ++ + 0
1. Hydrazinophthalazines
1-HP (as reference) 35 21 13 1 0
Ba 7441 33 13 14 6 0
Ba 6130 29 16 12 1 0
Ba7349 5 3 1 1 0
Ba13049 5 0 3 1 1
Ba7126 6 0 0 2 4
(necrosis)
Su2031 8 0 3 3 2
Ba12791 5 3 1 1 0
2. Hydrazino derivatives containing other ring
systems
1-HP (as reference) 41 26 15 0 0
Ba6905 6 2 0 1 3
Ba12890 6 1 0 3 2
Ba7406 7 1 4 2 0
Ba12664 8 0 4 0 4
Ba 6084 29 0 1 13 15
Ba13504 10 0 1 7 2
Su1998 29 0 1 0 28
Phenyihydrazine 35 0 0 2 33
Isoniazid 10 0 0 0 10
3. Phthalazines, without hydrazino groups
1-HP (as reference) 30 25 4 0 1
Ba7182 7 0 1 2 4
Su2106 30 1 0 0 29
Ba7127 7 0 0 2 5
Ba12668 6 0 0 1 5
Su2283 30 0 1 4 25
4. Miscellaneous
1-HP (as reference) 15 15 0 0 0
p-phenylenediamine 15 0 1 0 14
the aforementioned compounds with free hydrazino groups. However, the pen-
tavalent derivative, Ba 12791, was as potent as 1-HP.
3. The hypersensitivity was not directed against the hydrazino group as
such, since phenyl-hydrazine and 2-hydrazino-6-propyl-4-pyrimidol (Su 1998)
were completely devoid of cross-reacting properties. Replacement of the phthal-
azine nucleus by other ring systems markedly reduced or abolished the ability
to cross-react. Among these compounds, only 2-hydrazino-quinoline (Ba 12664),
I -hydrazino-isoquinoline (Ba 7406) and 4-hydrazino-cinnoline (Ba 6905) elicited
appreciable but much weaker reactions than those obtained with the specific
sensitizing compound. This indicates that the hypersensitivity is associated with
Experimental Group Number of Guinea.Pigs Used
Number of Animals with Various Degrees of
Delayed Type of Cutaneous Reaction
upon Challenge
+++ ++ + 0
9
16
3
0 0 0 9
4 5 4 3
0 0 0 3
Pre-fed
Not pre-fed
Controls
The control group consisted of animals not subjected to pre-feeding nor sensitization
with 1-HP.
the entire molecule and that the combination of both chemical constituents of
1-HP is necessary for the antigenic properties.
4. Phthalazino compounds lacking a hydrazino group failed to elicit cutaneous
reactions in sensitized guinea-pigs.
5. p-Phenylenediamine, which was included in this study in view of the pos-
sibility that under certain conditions, aromatic hydrazino compounds may be
metabolized to an amine, did not elicit any reaction in animals sensitive to
1-HP.
III. Inhibition of dermal sensitization by prior feeding of the sensitizing agent
Chase (12, 13) has reported that the feeding of 2, 3-dinitrochlorobenzene or
picryl chloride to normal guinea-pigs induces in these animals a state of resistance
against subsequent experimental sensitizations to the same agent. In view of
the practical importance of this observation, we investigated whether prefeeding
of 1-HP was likewise capable of preventing subsequent sensitizations to this
compound.
Nine guinea-pigs were fed, by pipette, a 2.5 % aqueous solution of 1-HP in
0.3 ml. amounts for 5 successive days. A second and third series of feedings were
then given, each after a week's interval. The animals were then sensitized with
1-HP as described above and challenged 25 days after the last sensitizing in-
jection. The results are noted in Table 4.
As indicated in Table 4, prefeeding of guinea-pigs with 1-HP before sensitiza-
tions protected them, as in Chase's experiments, against subsequent cutaneous
sensitizations.
DISCUSSION
The results of the experiments presented in this study indicate that 1-hy-
drazinophthalazine is a strong sensitizing agent for guinea-pigs, producing
sensitizations of the delayed type after a series of from 1 to 3 sensitizing injec-
tions. The ensuing sensitization is highly specific, extending only to substances
closely related to the primary sensitizing agent. It is directed not against a
single group but the entire molecule. The hydrazino group is as important as
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TABLE 4
Influence of pre-feeding with 1-hydrazinophthalazine on the degree of
subsequent sensitization with the same substance
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the presence of a double, nitrogen-bearing ring, such as a phthalazine-, quinoline-,
isoquinoline or cinnoline ring. It was surprising that this hypersensitivity was
not directed primarily against the hydrazino group because of its high chemical
and biological activity in this regard, as well as the well-known and strong al-
lergenic properties of phenyl-hydrazine. The high specificity suggests that the
directly active allergen is the unchanged molecule and not a metabolite with a
chemically altered hydrazino group.
Is it permissible to conclude from these results that similar sensitizations to
1-HP may occur in man following its therapeutic use? It is known that sub-
stances with strong skin sensitizing properties for humans are also powerful
sensitizers for the guinea-pig skin, as was demonstrated with primulin, phenyl-
hydrazine, para-phenylenediamine, dinitrochiorophenol, trinitrotoluene and
amino azodyes. Based upon this fact, it has long been assumed by numerous
investigators that conversely, substances which readily and strongly sensitize
the skin of guinea-pigs will prove to be strong sensitizers also for the human
when used as medicaments. On the basis of this belief, it has recently been sug-
gested that routine tests for skin sensitizing activities be made on all new drugs,
and then to regard with suspicion those substances found to exhibit strong al-
lergenic properties.
It is obviously impossible and in many instances objectionable to test the
allergenic properties of all prospective drugs in human volunteers (Mayer (14)).
The only animal in which such a test can be routinely performed is the guinea-
pig, the results of which may be indicative in certain cases, but certainly not in
all instances. We cannot conclude from a positive result in guinea-pigs that the
substance used as medicament will also sensitize the patient's skin. Indeed, the
experiments with 1-HP reveal obvious discrepancies between the positive ex-
perimental findings in guinea-pigs and the experiences accumulated during clin-
ical use of this compound. Contrary to what one would expect from the experi-
mental results, the number of skin sensitizations in patients arising from the
use of 1-HP has been, thus far, exceedingly low. Within the past year, of a
total of an estimated 400,000 patients treated with 1-HP, only 10 cases of
dermatitis medicamentosa which could be associated with a delayed type of
sensitization, have come to our knowledge. It seems, consequently, that we are
not justified in concluding from the results of laboratory experiments that a
substance proving highly sensitizing for the guinea-pig skin will produce an
alarming number of skin sensitizations in patients.
How may one explain the discrepancy between our observations made on
guinea-pigs and the clinical data gathered during its use as a medicament in
humans? Many observations indicate that it is not so much the strength of the
intrinsic sensitizing power of a substance which ultimately will determine
whether it can produce an undue number of skin sensitizations during its use
as a medicament in humans, but rather the nature of the exposure of the organism
to the allergenic substance, that is, the route of administration.
Procaine, for example, is a strong contact allergen and is responsible for a
great number of skin sensitizations among dentists, hut when used subeutane-
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ously as a local anesthetic, the incidence of sensitizations is much smaller.
Similarly, sulfonamides have produced considerably more sensitizations when
applied in the form of ointments than when taken internally. This is also the
case with penicillin, at least with respect to sensitizations of the delayed type.
The type of exposure not only determines the incidence of sensitizations but
also the type of allergy produced. A substance which regularly leads to sensitiza-
tion of the epidermis when used topically will predominantly produce asthma,
and only very few allergies of the skin when inhaled, as it occurs with para-
phenylenediamine, penicillin, neoarsphenamine and quinine (Mayer (15, 16)).
Although 1-HP has a high sensitizing property when administered directly
into the skin of guinea-pigs, in clinical use this medicament is never applied
topically to the skin, but given per os in the form of tablets; and only seldom
parenterally. It is this difference in exposure to 1-HP which, in our opinion,
explains the exceedingly low incidence of skin sensitizations of humans in spite
of its extensive clinical use, although this substance is intrinsically a strong and
powerful sensitizer for the guinea-pig skin. We may anticipate that the situation
would be quite different if 1-HP were intended for topical use.
On the other hand, the fact that 1-HP is not administered topically may not
be the only determinant for the low incidence of skin sensitizations during its
therapeutic use. It is quite probable that the prolonged oral administration of
this substance may confer a considerable protection against possible sensitiza-
tion. This is concluded from the results of the pre-feeding experiment, in which
oral administration of the allergen protected the animals against subsequent
sensitization with the substance.
The results of our experiments indicate that any skin sensitizing experiment
with prospective drugs must be interpreted with great care. One must consider
not only the intrinsic allergenic nature of the compound but also its proposed
clinical use and route of administration. A highly sensitizing agent will un-
doubtedly produce numerous allergic side effects on the skin when used topically
in the form of an ointment and its usefulness will be accordingly diminished
unless its therapeutic properties counterbalance the side effects. On the con-
trary, it may well be an excellent remedy for oral use and produce only very few
side effects, at least of the delayed type of allergic reaction. 1-hydrazinophthal-
azine is undoubtedly such a compound, since it produced strong sensitizations
of the skin in guinea-pigs but very few during its therapeutic use as a hypotensive
agent.
The situation is quite different when one must evaluate a product which fails
to sensitize the skin of guinea-pigs. While it is highly unlikely that such a sub-
stance used as a remedy will produce many side effects of the delayed allergic
type even when applied topically, it may nevertheless produce hypersensitivity
reactions of the immediate type such as urticaria, asthma, and even the more
serious symptoms of anaphylaxis.
Unfortunately, there exists at the present time, no method of animal experi-
mentation with compounds of low molecular weight, which would permit the
production of allergies of the anaphylactic type, suggestive of potential allergic
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properties of these substances for humans. Indeed, efforts to produce in guinea-
pigs such allergic side effects as the Nirvanol-disease or the usual anaphylactic
reactions with penicillin have been fruitless.
5UMMARY AND CONCLU5ION5
1. Intradermal injections of guinea-pigs with 1-hydrazinophthalazine regu-
larly produces generalized skin sensitizations of the delayed type. This sensi-
tization crosses over only to very closely related hydrazines, but not to phenyl-
hydrazine, normally a strong sensitizer.
2. Pre-feeding of 1-hydrazinophthalazine induces ill guinea-pigs a state of
resistance against subsequent sensitization to this drug.
3. No correlation exists between the results of tbese animal experiments and
the incidence of sensitization occurring during therapeutic use of this substance.
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